Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sparano

Showing results (441-450 of 560) with videos related to

Pageof 56
Sort By:
International Journal of Molecular Sciences|September 14, 2024
A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma PatientsDomenico Mallardo, Mario Fordellone, Andrew White, et al.
Journal of Translational Medicine|September 8, 2023
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapyDomenico Mallardo, Mario Fordellone, Andrew White, et al.
American Journal of Clinical Pathology|October 6, 2005
Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS casesRobert P Gormley, Rashna Madan, Alina E Dulau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classificationD Trapani, M A Franzoi, H J Burstein, et al.
Therapeutic Advances in Medical Oncology|March 26, 2021
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapyMorena Fasano, Carminia Maria Della Corte, Giuseppe Viscardi, et al.
Cancer|November 2, 2021
Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse eventsEdward H Ip, Santiago Saldana, Kathy D Miller, et al.
Breast Cancer Research and Treatment|June 7, 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancerYifan Tu, Dawn L Hershman, Kapil Bhalla, et al.
Cancer Immunology, Immunotherapy : CII|June 8, 2024
Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinomaDomenico Mallardo, Francesca Sparano, Maria Grazia Vitale, et al.
Andrology|April 6, 2026
Living Together, Loving Apart: Health, Sexuality and Relationships in Middle-Aged and Older Men in EuropeClotilde Sparano, Giammarco Alderotti, Giulia Rastrelli, et al.
Breast Cancer Research and Treatment|June 25, 2021
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancerMatthew Kearney, Lauren Franks, Shing Lee, et al.
Pageof 56

Showing results (441-450 of 560) with videos related to

Sort By:
Pageof 56
International Journal of Molecular Sciences|September 14, 2024
A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma PatientsDomenico Mallardo, Mario Fordellone, Andrew White, et al.
Journal of Translational Medicine|September 8, 2023
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapyDomenico Mallardo, Mario Fordellone, Andrew White, et al.
American Journal of Clinical Pathology|October 6, 2005
Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS casesRobert P Gormley, Rashna Madan, Alina E Dulau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classificationD Trapani, M A Franzoi, H J Burstein, et al.
Therapeutic Advances in Medical Oncology|March 26, 2021
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapyMorena Fasano, Carminia Maria Della Corte, Giuseppe Viscardi, et al.
Cancer|November 2, 2021
Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse eventsEdward H Ip, Santiago Saldana, Kathy D Miller, et al.
Breast Cancer Research and Treatment|June 7, 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancerYifan Tu, Dawn L Hershman, Kapil Bhalla, et al.
Cancer Immunology, Immunotherapy : CII|June 8, 2024
Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinomaDomenico Mallardo, Francesca Sparano, Maria Grazia Vitale, et al.
Andrology|April 6, 2026
Living Together, Loving Apart: Health, Sexuality and Relationships in Middle-Aged and Older Men in EuropeClotilde Sparano, Giammarco Alderotti, Giulia Rastrelli, et al.
Breast Cancer Research and Treatment|June 25, 2021
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancerMatthew Kearney, Lauren Franks, Shing Lee, et al.
Pageof 56